Sharp makes land acquisition to expand cGMP packaging capacity
The purchase is part of $17 million capacity expansion, which is in addition to a wider $43 million investment into the company's Pennsylvania operations
Global pharma contract packaging and clinical supply specialist Sharp has bought a four-acre plot of land directly adjacent to its Blistering Center of Excellence (comprising two commercial pharmaceutical packaging buildings) in Conshohocken, PA.
This land purchase is part of a $17 million capacity expansion, which Sharp said will enable it to add capacity to meet future demand for cGMP packaging services.
The transaction is also part of a wider $43 million investment into the company's Pennsylvania operations, which will increase its blister packaging capacity by more than 35% this year.
To date, the Conshohocken investment includes the construction and fit out of six new primary GMP rooms as well as fit out for secondary packaging and installation of new blister lines.
Only last month, Pennsylvania Governor Tom Wolf announced and supported Sharp's plan to increase manufacturing capacity by upgrading and partially re-purposing some of its four-facility Allentown campus, upgrade and obtain new machinery and equipment for its two-facility Conshohocken site, and make building improvements and obtain new machinery and equipment at its recently acquired 170,000-sq ft. facility in Macungie Borough.
In addition, Sharp expects to receive a $1.25 million state grant and a $140,000 grant to assist with worker training.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.